HITGEN

FBDD Case Studies

• We have pioneered the use of off-rate screening (ORS) to kinetically sample hit-

to-lead chemical space, combining our expertise in cheminformatics, compound

library synthesis and use of surface plasmon resonance (SPR), to enable

screening of unpurified reaction products. This has been applied to the rapid

generation of lead compounds from fragment hits without purification of

compound libraries or the use of protein structure (Murray, J. B. et al., J. Med.

Chem. 2014).

By combining structural, thermodynamic and kinetic information from the wide

range of ligand hits, we are able to design novel potent drug-like molecules. Our

successes include generation of lead compounds that inhibit protein-protein

interactions, ATPases and kinases, leading to clinical candidates for Mcl-1, Bcl-

2, Hsp90 and Chk1. Published examples of our novel technologies and approach

include use of our ORS technology in the identification of novel inhibitors of

PDHK, and using our expertise in protein engineering, expression and

crystallography to generate Chk1-derived surrogates of LRRK2.